In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing.
"synopsis" may belong to another edition of this title.
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
HRD. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L1-9783725867707
Quantity: Over 20 available
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
HRD. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L1-9783725867707
Seller: California Books, Miami, FL, U.S.A.
Condition: New. Seller Inventory # I-9783725867707
Seller: Rarewaves.com USA, London, LONDO, United Kingdom
Hardback. Condition: New. Seller Inventory # LU-9783725867707
Quantity: Over 20 available
Seller: CitiRetail, Stevenage, United Kingdom
Hardcover. Condition: new. Hardcover. In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Seller Inventory # 9783725867707
Quantity: 1 available
Seller: AHA-BUCH GmbH, Einbeck, Germany
Buch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. Seller Inventory # 9783725867707
Seller: Rarewaves.com UK, London, United Kingdom
Hardback. Condition: New. Seller Inventory # LU-9783725867707
Quantity: Over 20 available
Seller: Home-set, Mannheim, Germany
Gebundene Ausgabe. Condition: Neu. In the past decade, cancer immunotherapy has revolutionized the treatment of hematological and solid tumors, resulting in the approval of checkpoint inhibitory antibodies, CAR-T cell therapies, and T cells engaging bispecific antibodies. Despite this progress, the lack of response and/or relapse and subsequent resistance to immunotherapy remain major clinical challenges requiring the development of optimized therapeutic agents and novel principles for targeting cancer. For this purpose, the application of state-of-the-art antibody engineering continues to play a key role. This Special Issue covers recent progress and novel concepts in the engineering of antibody-based immunotherapies, including monoclonal antibodies, antibody engineering, bi- and multispecific antibodies, photo-and radioimmunotherapy and CAR-T cell therapy manufacturing. Sprache: Englisch Gewicht in Gramm: 608. Seller Inventory # IB-22172109
Seller: preigu, Osnabrück, Germany
Buch. Condition: Neu. Emerging Antibody Engineering Strategies and Applications for Immunotherapy of Cancer | Buch | Englisch | 2026 | MDPI AG | EAN 9783725867707 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. Seller Inventory # 134934030